<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    Biodesix’ Proteomic Analysis of Innovative Immunotherapy Clinical Trial in Pancreas Cancer presented at European Society of Medical Oncology’s (ESMO) World Congress on Gastrointestinal Cancer

    The first presentation of data resulting from a corporate partnership to explore development of a new diagnostic test based on Biodesix’ technology.

    Biodesix Announces New VeriStrat® Data to be Presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology

    Results from two phase II advanced lung cancer trials will be presented at the upcoming 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

    Biodesix’ Paul Beresford Joins 2012 BIO Panel for Personalized Medicine Commercialization

    Biodesix’ Paul Beresford will join industry veterans on a panel discussing the recipe for the successful commercialization of personalized medicine.

    Biodesix Receives 2011 North American Cancer Diagnostics Product Differentiation Excellence Award

    Biodesix received the Product Differentiation Excellence Award for its accomplishments in the cancer diagnostics industry.

    Biodesix Receives New EU and US Patents for Blood-based Oncology Tests

    Biodesix announced the issuance of three additional patents. Two which provide intellectual property protection and the other for Veristrat.

    VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer

    VeriStrat test was able to identify patients likely to have better and worse survival outcomes when treated with the combination therapy.

    VeriStrat® Test Predicts Outcomes in Advanced Breast Cancer Patients

    Veristrat can be used to identify a group of patients with worse progression-free (PFS) when treated with Femera alone, independent of Her2 status.

    Biodesix Relocates to Boulder, CO

    Biodesix, Inc., today announced the relocation of their corporate headquarters from Broomfield, Colorado to Boulder, Colorado.

    Biodesix Appoints Vice President of Clinical Development & Medical Affairs

    Biodesix announced the appointment of Dominic Spinella, Ph.D., as Vice President of Clinical Development & Medical Affairs.

    Biodesix Announces Phase 3 Clinical Trial Collaboration with Kadmon

    Biodesix today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 (NSCLC).